Aggressive fi bromatosis (desmoid tumor) of the neck is rare. When feasible, surgery is the best treatment option. However, complete excision with negative margins is not possible in most cases because of the involvement of vascular and nervous structures. Also, surgery results in poor functional and aesthetic outcomes. Sometimes debulking surgery with positive margins is performed, but the anatomy of the neck is a challenge for oncologic surgeons, and recurrences are not uncommon. Radiotherapy is seldom employed for the same reasons. On the other hand, systemic treatment with chemotherapy, hormone therapy, and noncytotoxic agents such as nonsteroidal anti-infl ammatory drugs (NSAIDs) has been used with good results. We report a case of inoperable aggressive fi bromatosis of the neck that was successfully treated for about 21 months with a combination of chemotherapy and the NSAID indomethacin. As far as we know, this is the fi rst reported use of a combination of chemotherapy and an anti-infl ammatory drug in the treatment of aggressive fi bromatosis of the neck. We also review the literature on cases of aggressive fi bromatosis of the neck that have been reported over the past 12 years. * Present case.
Introduction
Aggressive fi bromatosis (also called desmoid tumor because of its tendon-like appearance) is a benign entity that accounts for approximately 0.03% of all neoplasms and fewer than 3% of all soft -tissue tumors. [1] [2] [3] Positive prognostic factors include the presence of a primary tumor as opposed to a recurrence and treatment with wide excision and negative margins. 4 When feasible, surgery is the preferred treatment for both primary disease and recurrences.
Aggressive fi bromatosis is characterized by the presence of an infi ltrative tumor similar to a low-grade sarcoma. When such tumors are removed with close margins, they have a strong tendency to recur. However, wide excision is not always possible without causing major complications or disability, and the benign nature of these lesions does not justify radical surgery. When the margins are too close to the tumor, postoperative radiotherapy is indicated to reduce the risk of local recurrence. However, even radiotherapy can be problematic in diffi cult locations such as the neck in terms of functional and cosmetic results. Chemotherapy is indicated in selected cases, and observation is an option in patients with a slowly growing tumor or with a tumor in a low-risk site. 5 Diff erent systemic therapies have been studied for inoperable cases of desmoid tumor. Th ey include chemotherapy with various drugs (methotrexate in combination with doxorubicin, ifosfamide, and/or vinblastine or vinorelbine), antiestrogens, nonsteroidal anti-infl ammatory drugs (NSAIDs) (e.g., indomethacin, sulindac, and cyclo-oxygenase-2 [COX-2] inhibitors), interferons and, more recently, target therapy with imatinib for platelet-derived growth factor receptorbeta (PDGFR-β) -positive tumors. 6 Low-dose chemotherapy with methotrexate and vinblastine (or its less neurotoxic analog vinorelbine) on a weekly basis has been shown to achieve a 70% relapse-free interval at 10 years. 2, 5 Likewise, indomethacin has been reported to be eff ective in some cases of desmoid tumor. For example, Waddell and Gerner reported 2 such cases; in 1 of these believe that surgery was feasible because the mass was too close to vital and functional structures such as the jugular vein, carotid artery, and the brachial plexus to allow for wide excision. Th erefore, we chose to treat with chemotherapy, with the understanding that surgery would be reconsidered if necessary. Th e patient was started on intravenous methotrexate at 30 mg/m 2 in 100 ml of saline solution followed by IV vinblastine at 6 mg/ m 2 in 100 ml of saline once weekly for 8 weeks, followed by 1 week of rest before the initiation of a new cycle. 5 A blood count was obtained before each chemotherapy session. In addition, oral indomethacin at 100 mg/day was prescribed to alleviate the neck pain. Th e indomethacin was also used with a curative intent in view of its reported eff ectiveness in treating aggressive fi bromatosis. 7, 8 Th e patient did not tolerate oral antiemetics; she experienced fatigue and drowsiness aft er trying both ondansetron and metoclopramide. Therefore, her antiemetic regimen was switched to 4 mg of IV dexamethasone, which was administered just prior to each infusion of methotrexate and vinblastine. During the fi rst two cycles, the chemotherapy itself was well tolerated; no G3 or G4 toxicity was reported, and no dose reduction was necessary.
Th e fi rst follow-up evaluation was performed aft er 4 months of treatment-that is, aft er 2 cycles of 8 weeks each. A follow-up MRI obtained at this time revealed that the mass had shrunk by 20%. Th e patient also reported relief of pain and improvement in her neck and shoulder motion. Aft er 17 months of additional treatment with chemotherapy plus indomethacin, the disease had stabilized. Follow-up MRI revealed a marked reduction in the size of the mass to 4 × 6.5 × 8 cm (fi gure, B). In 2 patients, 5 g of ascorbic acid was added aft er disease progression, and a second remission was reported that lasted 14 months. 7 We report a new case of aggressive fi bromatosis of the neck that was treated with a unique combination of systemic drugs. We also review the cases of desmoid tumor of the neck that have been reported since 1999.
Case report
A 32-year-old married woman with no children and an otherwise unremarkable medical history was referred to our institute in March 2006 with a huge painful mass on the left side of her neck. She said that the mass had been growing slowly there for the previous 17 months.
Magnetic resonance imaging (MRI) obtained 1 month prior to referral demonstrated an 8 × 8 × 11-cm soft -tissue mass in the left side of the neck (fi gure, A). Its signal intensity was similar to that of muscle on T1-weighted imaging, and it demonstrated marked homogeneous enhancement on contrast. Th e mass extended irregularly into the adjacent scalene, rhomboid, levator scapula, and multifi dus muscles.
On examination, the patient had much diffi culty moving her neck and left shoulder. Th e pain and limitation of motion she experienced had resulted in a poor quality of life. She reported that she had been taking diff erent pain medications. Fine-needle aspiration biopsy revealed atypical spindle-shaped cells of fi broblastic origin and dense collagenous fi bers consistent with an aggressive fi bromatosis. Immunostaining was focally positive for PDGFR-β, and positive for estrogen receptors, progesterone receptors, and beta-catenine.
We consulted an orthopedic surgeon, who did not 
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December 2007, treatment was discontinued, and the patient was monitored every 6 months thereaft er. Th e patient continued taking indomethacin, which was well tolerated. MRIs of the neck obtained 6 and 12 months aft er the cessation of chemotherapy showed that disease was stable and still in remission. Th e patient was taken off indomethacin in January 2009, and she was satisfi ed with the functional and clinical result. In all, our patient had been administered 10 cycles (80 weekly doses) of chemotherapy. We were able to reduce the size of the doses by 20% over the fi nal 8 cycles (15% reduction of all-dose intensity). A 1-week delay in starting the sixth chemotherapy cycle was necessary because of toxicity issues (hypertransaminasemia and leukopenia) and again later because of a skin infection. Th e maximum hepatic toxicity value for both the increase in transaminase level and the leukopenia was G2. Also, aft er 18 months of chemotherapy, the patient complained of a slight peripheral neuropathy caused by the vinblastine; the neuropathy disappeared 6 months aft er the cessation of chemotherapy.
At follow-up in June 2010, 4 years and 3 months aft er the start of treatment, the patient's disease was stable and she was asymptomatic. However, in November 2010, she began to notice a recurrence of shoulder pain. An MRI obtained in December 2010 showed no change in the previous neck mass, but a new mass had arisen anteriorly. Th e orthopedic service judged both masses to be inoperable, and in January 2011, the patient was restarted on chemotherapy with methotrexate at 30 mg/m 2 and vinorelbine (which is less neurotoxic than vinblastine) at 20 mg/m 2 . Th e patient demonstrated clinical and objective (MRI) initial improvement, and in April 2011 she remained on treatment.
Discussion
Desmoid tumor is a tumor of mesenchymal origin that develops as a result of an abnormal proliferation of fi broblasts and myofi broblasts in abundant collagen. It occurs in musculoaponeurotic structures. It is a tumor of intermediate malignancy, situated along the spectrum between benign fi brous tissue and fi brosarcoma.
Th e abdomen is aff ected in two-thirds of cases. Th e most common extra-abdominal sites are the trunk and associated girdles. Th e neck is aff ected in 8 to 15% of extra-abdominal cases. 2 Th e median age at onset is 30 years (range: 15 to 60). 2 Aggressive fi bromatosis is most common in women of child-bearing age, and the maleto-female ratio is 3 to 1. 2 Th e etiology of desmoid tumor is unknown. In 63% of cases, there is a history of surgical trauma. 1 Also, estrogen receptors are involved in 30% of cases, suggesting that hormones play an etiologic role. 6 Hormones can also play a role in the treatment of this tumor, as human studies have shown a response to antiestrogen therapy in 30 to 50% of cases. 9 As mentioned, the treatment of choice is surgery when feasible. When radiotherapy is administered, it is usually employed aft er surgery, although sometimes it is administered alone in inoperable cases or as an adjuvant following surgery with positive margins. 2 However, Nuyttens et al conducted a comparative review of 22 articles involving a total of 780 patients with a median follow-up of 6 years. 10 Th ey found that local control rates were 78% for patients who were treated with radiotherapy alone and 75% for those treated with surgery plus radiotherapy, compared with only 61% for patients who were treated with surgery alone. Th e authors concluded that radiotherapy with or without surgery was signifi cantly more eff ective in this regard than surgery alone. Nevertheless, other authors have diff erent opinions. Hosalkar et al argued that the side eff ects of radiotherapy (fi brosis, a second malignancy) make low-dose chemotherapy a better and safer option. 2 Meazza et al reported that radiotherapy is especially preferable in pediatric cases. 11 Reported recurrence rates for aggressive fi bromatosis of the head and neck range from 25 to 86%, with the highest incidence occurring in the supraclavicular and cervical areas. 12, 13 Masson and Soule reported a 70% recurrence rate in the head and neck, compared with a 50% rate in other anatomic sites. 12 Some of the higher recurrence rates in the head and neck can be attributed to the proximity of tumors to vital structures, which can make dissection extremely complicated and oft en suboptimal.
We reviewed the English-language literature since 1999 and found 77 previously reported cases of desmoid tumor of the neck (table). [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Radiotherapy was employed in only 16 of those cases. Systemic treatment in these previously reported cases has included chemotherapy, an NSAID, and hormone therapy with or without an NSAID; to the best of our knowledge, ours is the fi rst published case of a desmoid tumor of the neck that was treated with a combination of low-dose chemotherapy (methotrexate and vinblastine) combined with an NSAID (indomethacin). Gega et al published a study of 7 patients with familial adenomatous polyposis associated with intra-abdominal aggressive fi bromatosis who had failed previous hormone therapy; all 7 patients were successfully treated with doxorubicin and dacarbazine followed by the COX-2 inhibitor meloxicam. 29 Our patient responded well to treatment with minimal side eff ects and good tumor control for a prolonged time, and she experienced a good functional and clinical result.
We believe that in cases where even a slight increase in tumor volume might compromise life and when conservative treatment is preferred for functional and/ or cosmetic reasons or when a complete resection is not feasible, low-dose chemotherapy combined with an NSAID is a low-toxicity option to control disease for a prolonged time. We believe that low-dose chemotherapy with methotrexate and vinblastine or vinorelbine is well tolerated and could be readministered at relapse if longterm eff ectiveness (~3 years in our case) is observed. 
